Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.
Dendritic cells (DCs) are important antigen-presenting cells (APCs) that can prime naive T cells and control adaptive immune responses with respect to magnitude, memory and self-tolerance. Understanding the biology of these cells is central to the development of new generation immunotherapies for cancer and chronic infections. This review presents a brief overview of DC biology and of the preparation and use of DC-based vaccines.
O'Neill
David W
DW
Pathology, New York University School of Medicine, Rusk Research Bldg., Room 718, 400 East 34th Street, NewYork, NY 10016, USA. david.o'neill@med.nyu.edu
Bhardwaj
Nina
N
D017951:Antigen Presentation; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002908:Chronic Disease; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D007239:Infections / Q000628:therapy*; D009369:Neoplasms / Q000628:therapy*; D014612:Vaccines / Q000276:immunology / Q000627:therapeutic use*
D019496:Cancer Vaccines; D014612:Vaccines